Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/NNE.0000000000000743 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Molecular heterogeneity in urothelial carcinoma and determinants of clinical benefit to PD-L1 blockade.
Cancer Cell
December 2024
Genentech, South San Francisco CA, USA. Electronic address:
Checkpoint inhibitors targeting programmed cell death protein 1 (PD-1)/programmed death-ligand 1 (PD-L1) have revolutionized cancer therapy across many indications including urothelial carcinoma (UC). Because many patients do not benefit, a better understanding of the molecular mechanisms underlying response and resistance is needed to improve outcomes. We profiled tumors from 2,803 UC patients from four late-stage randomized clinical trials evaluating the PD-L1 inhibitor atezolizumab by RNA sequencing (RNA-seq), a targeted DNA panel, immunohistochemistry, and digital pathology.
View Article and Find Full Text PDFDigital tools in heart failure: addressing unmet needs.
Lancet Digit Health
October 2024
National Heart Centre Singapore, Singapore; Duke-National University of Singapore, Singapore; Baim Institute for Clinical Research, Boston, MA, USA. Electronic address:
Article Synopsis
- * The rise of technology and global connectivity supports the use of these tools, yet challenges persist in treatment effectiveness, especially in lower-income regions.
- * To maximize the benefits of digital health tools, it's essential to create supportive systems and clinical frameworks that can be applied worldwide.
Imaging with [Zr]Zr-DFO-SC16.56 anti-DLL3 antibody in patients with high-grade neuroendocrine tumours of the lung and prostate: a phase 1/2, first-in-human trial.
Lancet Oncol
August 2024
Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Molecular Pharmacology Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA; Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA. Electronic address:
Background: Delta-like ligand 3 (DLL3) is aberrantly expressed on the surface of small-cell lung cancer (SCLC) and neuroendocrine prostate cancer cells. We assessed the safety and feasibility of the DLL3-targeted imaging tracer [Zr]Zr-DFO-SC16.56 (composed of the anti-DLL3 antibody SC16.
View Article and Find Full Text PDFThe importance of LDL-C lowering in atherosclerotic cardiovascular disease prevention: Lower for longer is better.
Am J Prev Cardiol
June 2024
Department of Medicine, Johns Hopkins Hospital, Baltimore, MD, United States.
Cumulative exposure to low-density lipoprotein cholesterol (LDL-C) is a key driver of atherosclerotic cardiovascular disease (ASCVD) risk. An armamentarium of therapies to achieve robust and sustained reduction in LDL-C can reduce ASCVD risk. The gold standard for LDL-C assessment is ultracentrifugation but in routine clinical practice LDL-C is usually calculated and the most accurate calculation is the Martin/Hopkins equation.
View Article and Find Full Text PDFA web-based geographic information system monitoring wildlife diseases in Abruzzo and Molise regions, Southern Italy.
BMC Vet Res
October 2023
Istituto Zooprofilattico dell'Abruzzo e del Molise "G. Caporale", Teramo, Italy.
Background: Nowadays there is a worldwide consensus on the importance of conducting wildlife disease surveillance. Indeed, 60% of emerging infectious diseases are zoonotic in nature, and the majority of these (71.8%) originate in wildlife.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!